Found: 12
Select item for more details and to access through your institution.
Human interferon alpha in malignant lymphoma and Hodgkin's disease. Results of the American Cancer Society trial.
- Published in:
- 1985
- By:
- Publication type:
- journal article
Skin rash following therapy with mitomycin C.
- Published in:
- 1984
- By:
- Publication type:
- journal article
CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties.
- Published in:
- International Journal of Nanomedicine, 2019, v. 14, p. 3819, doi. 10.2147/IJN.S139450
- By:
- Publication type:
- Article
Phase IIB Randomized Study of CPX-351 Versus Conventional Cytarabine + Daunorubicin in Newly Diagnosed AML Patients Aged 60-75: An Interim Analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2010, v. 10, n. 3, p. E28, doi. 10.3816/CLML.2010.n.038
- By:
- Publication type:
- Article
Outcomes in Older Patients with Newly Diagnosed, High-risk/Secondary Acute Myeloid Leukemia (sAML) Who Received Consolidation in a Phase 3 Study of CPX-351 versus Conventional 7+3/5+2 Cytarabine and Daunorubicin.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S208, doi. 10.1016/j.clml.2018.07.064
- By:
- Publication type:
- Article
A Phase 3 Study of CPX-351 versus Conventional 7+3 Cytarabine and Daunorubicin: Subanalysis of Patients with Secondary Acute Myeloid Leukemia (sAML) with Refractory Anemia with Excess of Blasts in Transformation (RAEB-t).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S208, doi. 10.1016/j.clml.2018.07.063
- By:
- Publication type:
- Article
Overall Survival (OS) and Stem Cell Transplant (SCT) in Patients with FLT3 Mutations Treated with CPX-351 versus 7+3: Subgroup Analysis of a Phase 3 Study of Older Adults with Newly Diagnosed, High-Risk Acute Myeloid Leukemia (AML).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S286, doi. 10.1016/j.clml.2017.07.071
- By:
- Publication type:
- Article
Overall Survival (OS) by Outpatient versus Inpatient Consolidation in a Phase 3 Study of CPX-351 versus 7+3 in Older Adults with Newly Diagnosed, High-Risk Acute Myeloid Leukemia (AML).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S287, doi. 10.1016/j.clml.2017.07.073
- By:
- Publication type:
- Article
Efficacy and Safety of CPX-351 versus 7+3 in Older Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (tAML): Subgroup Analysis of a Phase 3 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S288, doi. 10.1016/j.clml.2017.07.074
- By:
- Publication type:
- Article
A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
- Published in:
- Cancer (0008543X), 2015, v. 121, n. 2, p. 234, doi. 10.1002/cncr.28974
- By:
- Publication type:
- Article